PolyMyXin-B direct hemoperfusion OPTimal Initiation timing with Catecholamine study (PMX-OPTIC study)

PolyMyXin-B direct hemoperfusion OPTimal Initiation timing with Catecholamine study (PMX-OPTIC study) - PMX-OPTIC study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051464

Enrollment

600

Registered

2023-06-27

Start date

2022-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic shock

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years and older admitted to the ICU. 2. Patients treated with PMX for septic shock (diagnosed based on Sepsis-3 criteria). 3. Patients using vasopressor at the time of PMX initiation. 4. Patients who underwent their first PMX during the same hospitalization.

Exclusion criteria

Exclusion criteria: 1. Cases of End of Life/Terminal Care where treatment was not the primary objective. 2. Patients who received interventions for circulatory support such as ECMO, VAD, IMPELLA (excluding IABP).

Design outcomes

Primary

Measure	Time frame
28-day mortality rate	—

Secondary

Measure	Time frame
7-day survival rate Length of hospital stay Length of ICU stay Duration of mechanical ventilation CRP/Albumin/Lymphocyte count on the 14th day after ICU admission (closest to the 14th day based on blood samples collected between the 11th and 17th day)	—

Countries

Japan

Contacts

Public ContactKensuke Nakamura

Teikyo University Department of Emergency Medicine

mamashockpapashock@yahoo.co.jp03-3964-1211

Outcome results